KRAS and neoplasm: By modifying with iRGD, we induced BiTE-mediated inward flow of activated effector T cells, specifically targeting the KRAS G12V mutation and improving tumor tissue penetration to address the problem of limited efficacy due to insufficient effector cells infiltration.